Vontobel Holding Ltd. Makes New Investment in Repare Therapeutics Inc. (NASDAQ:RPTX)

Vontobel Holding Ltd. acquired a new position in shares of Repare Therapeutics Inc. (NASDAQ:RPTX) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 15,000 shares of the company’s stock, valued at approximately $110,000.

Other hedge funds also recently added to or reduced their stakes in the company. Barclays PLC acquired a new stake in shares of Repare Therapeutics in the 2nd quarter valued at approximately $36,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Repare Therapeutics in the 3rd quarter valued at approximately $149,000. Exchange Traded Concepts LLC lifted its holdings in shares of Repare Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 13,585 shares of the company’s stock valued at $99,000 after buying an additional 3,445 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Repare Therapeutics by 30.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,919 shares of the company’s stock valued at $180,000 after buying an additional 3,493 shares during the period. Finally, Blackstone Inc. lifted its holdings in shares of Repare Therapeutics by 14.9% in the 3rd quarter. Blackstone Inc. now owns 25,957 shares of the company’s stock valued at $314,000 after buying an additional 3,362 shares during the period. 85.09% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RPTX has been the subject of several recent analyst reports. Bloom Burton raised Repare Therapeutics from an “accumulate” rating to a “buy” rating in a report on Friday, April 19th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Repare Therapeutics in a report on Wednesday, February 21st.

Repare Therapeutics Price Performance

NASDAQ RPTX opened at $3.30 on Thursday. Repare Therapeutics Inc. has a 1-year low of $2.98 and a 1-year high of $13.85. The company has a market capitalization of $122.10 million, a P/E ratio of -1.48 and a beta of 0.56. The business has a 50 day moving average price of $5.05 and a 200 day moving average price of $5.59.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.11). Repare Therapeutics had a negative net margin of 183.43% and a negative return on equity of 39.82%. The firm had revenue of $13.05 million during the quarter, compared to analysts’ expectations of $15.92 million. On average, research analysts expect that Repare Therapeutics Inc. will post -2.74 earnings per share for the current fiscal year.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.